Methotrexate for Alopecia Areata

Methotrexate is a systemic immunomodulatory medication that has been used for decades in autoimmune and inflammatory disease. It is also an established chemotherapy drug at substantially higher doses.

In alopecia areata, methotrexate is used at much lower weekly doses with the goal of suppressing the immune activity directed against susceptible hair follicles. It can be used alone, but much of the clinical literature suggests that its most useful role may be as part of a steroid sparing strategy, particularly when systemic corticosteroids produce regrowth that cannot be maintained without continued steroid exposure.

Methotrexate is not FDA approved for alopecia areata. Its use for hair loss is off label.

Current international guidance nevertheless recognizes methotrexate as a legitimate systemic option for selected patients with moderate, severe or very severe alopecia areata. The evidence suggests that methotrexate alone can produce partial or meaningful regrowth in some patients, but controlled modern evidence in chronic alopecia totalis and universalis has been considerably less impressive than older observational response rates might suggest. Combination treatment with systemic corticosteroids has generally produced stronger complete response rates.

The medication is inexpensive and has decades of clinical experience behind it, but it should not be treated as a simple hair growth drug. Methotrexate can affect the bone marrow, liver, lungs, kidneys, gastrointestinal tract, immune system and reproductive system. It also requires regular laboratory monitoring and careful attention to dosing because serious and even fatal medication errors have occurred when a weekly dose was mistakenly taken every day.

What Is Methotrexate?

Methotrexate is an antimetabolite and folate antagonist that was originally developed for cancer treatment. At high doses it interferes with rapidly dividing cells and remains an important component of treatment for several cancers.

At much lower weekly doses, methotrexate is widely used as a disease modifying antirheumatic drug, or DMARD, in conditions such as rheumatoid arthritis, juvenile idiopathic arthritis and severe psoriasis.

Its effects at these lower doses are more complex than simply blocking cell division. Methotrexate alters folate dependent metabolism and influences several inflammatory and immune pathways. Increased extracellular adenosine signaling is believed to contribute substantially to its anti inflammatory activity, and research also suggests effects on T cells and other immune signaling pathways.

The exact mechanism responsible for improvement in alopecia areata has not been completely established.

Is Methotrexate Chemotherapy?

It is the same medication used in chemotherapy, but the dose and treatment objective are very different.

Cancer regimens can involve doses many times greater than the weekly doses typically used for autoimmune disease. When methotrexate is prescribed for alopecia areata, it is generally being used as a low dose immunomodulatory medication rather than as conventional cancer chemotherapy.

That distinction is important, but it should not be used to trivialize the drug. Low dose methotrexate can still cause serious toxicity and requires medical supervision, laboratory monitoring and careful attention to interactions and reproductive safety.

Is Methotrexate FDA Approved for Alopecia Areata?

No.

Methotrexate is FDA approved for several cancers and for noncancer conditions including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe psoriasis. It does not have an FDA approved indication for alopecia areata.

Its use for alopecia areata is therefore off label. There is no FDA established methotrexate dose or monitoring schedule specifically for alopecia areata. Dosing recommendations used in hair loss practice come from alopecia areata studies, international guidelines and experience with low dose methotrexate in other inflammatory diseases.

Why Is Methotrexate Used for Alopecia Areata?

Alopecia areata is an autoimmune form of nonscarring hair loss in which immune activity interferes with normal hair follicle cycling.

Methotrexate suppresses and modifies immune activity rather than directly stimulating the hair follicle. When the immune attack is sufficiently controlled, susceptible follicles may return to productive growth.

This is fundamentally different from the way minoxidil is used as a hair growth promoter or the way finasteride and dutasteride influence androgen metabolism in pattern hair loss.

Methotrexate is treating an autoimmune disease.

Who Is Most Likely to Be Considered for Methotrexate?

Methotrexate is generally considered for patients with moderate to severe alopecia areata rather than for someone with one or two small stable patches.

Current international guidance supports methotrexate as a systemic option for adults with moderate, severe or very severe alopecia areata. Its role becomes particularly relevant when disease is extensive, persistent, repeatedly relapsing, difficult to treat locally or when prolonged dependence on systemic corticosteroids needs to be avoided.

The 2026 German S3 guideline gives stronger recommendation language to methotrexate combined with systemic corticosteroids than to methotrexate monotherapy in adults with moderate to very severe disease. It advises against systemic methotrexate for mild adult alopecia areata.

That distinction makes clinical sense. A patient with limited disease may respond to intralesional or topical corticosteroids without exposure to a systemic immunomodulatory medication requiring long term laboratory monitoring.

What Dose of Methotrexate Is Used for Alopecia Areata?

There is no FDA approved methotrexate dose for alopecia areata.

Current international guidance generally describes an adult target dose of approximately 15 to 25 mg once weekly. Other published studies have used doses within this general range.

The major randomized trial in chronic alopecia totalis and alopecia universalis used oral methotrexate at 20 or 25 mg once weekly according to patient weight.

The appropriate dose depends on the patient’s age, body size, kidney function, response, adverse effects and other medical factors. The existence of a 25 mg upper range does not mean every patient should automatically receive 25 mg.

Methotrexate Is Taken Weekly, Not Daily

This is one of the most important safety issues associated with methotrexate.

For inflammatory and autoimmune conditions, methotrexate is generally taken once weekly, not once daily. Fatal medication errors have occurred when patients accidentally took a weekly methotrexate dose every day.

Patients should know exactly which day of the week methotrexate is supposed to be taken and should confirm the instructions whenever there is any uncertainty.

A prescription for several tablets does not mean the tablets should automatically be distributed throughout the week. Depending on the prescribed dose and tablet strength, several tablets may together make up the single weekly dose.

How Effective Is Methotrexate for Alopecia Areata?

Methotrexate has a meaningful evidence base, but much of the older literature comes from observational studies rather than large modern placebo controlled trials.

A 2019 systematic review and meta analysis pooled studies involving patients with severe alopecia areata and reported complete regrowth in approximately 35.8 percent overall. Complete response was approximately 44.7 percent in adults and 11.6 percent in children.

Those figures need substantial qualification.

The studies used different doses, treatment durations, definitions of response and corticosteroid combinations. Many were retrospective or uncontrolled. Spontaneous fluctuation in alopecia areata also makes treatment response difficult to interpret without a control group.

More recent randomized evidence in chronic alopecia totalis and universalis produced a much less impressive picture of methotrexate monotherapy. The most useful conclusion is therefore not that roughly one third or one half of patients should expect complete regrowth. It is that methotrexate can produce meaningful disease control in selected patients, but response is variable and the older pooled percentages should not be treated as modern monotherapy success rates.

Does Methotrexate Work Better With Corticosteroids?

The available evidence suggests that combination therapy can produce stronger results than methotrexate alone.

The 2019 meta analysis found a greater likelihood of response when methotrexate was combined with systemic corticosteroids. Smaller comparative studies have also supported greater disease reduction with combination treatment.

This is one reason methotrexate has traditionally been used as a steroid sparing treatment.

A corticosteroid can provide relatively rapid suppression of active disease while methotrexate begins exerting a slower longer term immunomodulatory effect. The corticosteroid can then potentially be reduced or discontinued rather than becoming indefinite maintenance treatment.

This does not mean that every patient taking methotrexate should also receive prednisone. Combining systemic medications also combines risk, and the rationale should be individualized.

What Did the 2023 Randomized Trial Show?

The strongest modern trial of methotrexate in severe alopecia areata was a multicenter double blind randomized study involving 89 adults with chronic alopecia totalis or alopecia universalis.

These were patients with severe and difficult to treat disease that had persisted for more than six months despite previous topical and systemic treatment.

Patients initially received oral methotrexate at 20 or 25 mg once weekly according to body weight or placebo.

Methotrexate monotherapy was not highly effective at producing complete regrowth in this difficult population. At month 12, only one patient met the primary endpoint of complete or almost complete regrowth while remaining on methotrexate alone. Another patient experienced complete regrowth earlier in treatment but was subsequently lost to follow up. Partial regrowth occurred in additional patients, but the trial clearly demonstrated that methotrexate alone was not a reliably effective treatment for chronic alopecia totalis or universalis.

Patients without adequate early response were subsequently treated with methotrexate combined with low dose prednisone or methotrexate with placebo.

Among 35 patients receiving methotrexate plus prednisone, 7, or 20 percent, achieved complete or almost complete hair regrowth. In the subgroup receiving methotrexate for 12 months with prednisone added during the final six months, 5 of 16 patients, approximately 31 percent, achieved complete or nearly complete regrowth.

This study is important because it places the older observational literature into perspective. Methotrexate has real activity, but its reputation as a monotherapy was built largely from studies less rigorous than this randomized trial. Its steroid sparing and combination role may therefore be at least as important as its use alone in chronic severe disease.

Does That Mean Methotrexate Should Always Be Combined With Prednisone?

No.

Combination therapy may provide better efficacy in some patients, but prednisone carries its own substantial short and long term adverse effects.

The reason for using methotrexate alongside corticosteroids is generally not to keep both medications at substantial exposure indefinitely. The objective is often to gain control of active autoimmune disease and then reduce corticosteroid exposure while attempting to maintain disease control with the steroid sparing medication.

Some patients may receive methotrexate alone when prolonged corticosteroid treatment is undesirable or when disease characteristics and medical history favor that approach.

How Long Does Methotrexate Take to Work?

Methotrexate is not a rapid hair growth treatment.

Clinical improvement in inflammatory diseases often requires weeks to months, and alopecia areata adds the additional delay created by the hair growth cycle.

In alopecia areata studies, diffuse regrowth has sometimes begun within several months. The 2023 randomized trial also demonstrated that meaningful methotrexate responses could take months to emerge.

Complete regrowth in responders may take considerably longer.

A patient should not assume that methotrexate has failed because visible hair has not returned after several weeks. At the same time, systemic treatment should not continue indefinitely without objective evidence that disease activity or hair growth is improving.

How Should Response Be Measured?

Standardized photography is useful for documenting whether scalp coverage is actually improving.

For more extensive disease, the Severity of Alopecia Tool, or SALT score, can provide a standardized measure of the percentage of scalp hair loss. Eyebrow and eyelash involvement should also be documented when relevant.

Objective measurement becomes especially important with methotrexate because the treatment carries enough systemic risk that continuing it without evidence of benefit is difficult to justify.

What Happens if Methotrexate Is Stopped?

Relapse is common.

The 2019 meta analysis reported recurrence in approximately 47.7 percent of patients overall and approximately 52 percent of adults. In children, pooled recurrence was lower, at approximately 31.7 percent.

The individual studies were heterogeneous, so these percentages should not be interpreted as precise predictions for a particular patient. Many relapses occurred after methotrexate or accompanying corticosteroid treatment was reduced or discontinued.

The larger point is important. Methotrexate can control autoimmune activity, but it does not permanently eliminate the biological susceptibility to alopecia areata.

Hair regrowth while taking methotrexate should therefore not automatically be interpreted as a permanent cure.

Does Methotrexate Have to Be Continued Long Term?

Sometimes.

If methotrexate is successfully controlling severe alopecia areata, continued treatment may be necessary to maintain the benefit.

That does not mean treatment should automatically continue indefinitely. The physician must continually balance disease control against cumulative exposure, laboratory findings, adverse effects and the availability of alternative treatments.

The goal should be the lowest effective sustainable treatment strategy, not indefinite immunosuppression simply because hair loss returns whenever medication is reduced.

What Is Folic Acid and Why Is It Given With Methotrexate?

Methotrexate interferes with folate metabolism.

For low dose methotrexate used in inflammatory disease, folic acid or folinic acid supplementation is commonly prescribed to reduce adverse effects such as mouth sores, gastrointestinal symptoms and some laboratory abnormalities without meaningfully undermining the anti inflammatory effect.

Current U.S. prescribing information specifically recommends folic acid or folinic acid supplementation for several approved noncancer uses of methotrexate.

There is no FDA established folic acid regimen specifically for alopecia areata. The exact dose and schedule vary among physicians and treatment protocols.

Patients should therefore take the supplementation regimen prescribed by their physician rather than independently changing the amount or timing.

What Blood Tests Are Needed?

Methotrexate requires ongoing laboratory monitoring.

Before treatment begins, physicians commonly evaluate a complete blood count, liver function and kidney function. Pregnancy status must be established in women who could become pregnant.

Additional screening for hepatitis, tuberculosis or other infections may be appropriate depending on medical history, risk factors and the planned degree of immunosuppression.

During treatment, complete blood counts, liver enzymes and kidney function are monitored periodically. Monitoring is generally more frequent after treatment begins or after dose changes and can become less frequent once treatment and laboratory results are stable.

Patients with additional risk factors such as older age, diabetes, kidney impairment, obesity, heavy alcohol use or other hepatotoxic or bone marrow suppressing medications may require closer monitoring.

There is no FDA laboratory schedule specifically designed for alopecia areata, so the exact approach should be individualized.

Why Is the Complete Blood Count Important?

Methotrexate can suppress bone marrow function.

This can reduce white blood cells, red blood cells or platelets and, in severe cases, produce pancytopenia.

A low white blood cell count can increase infection risk. A low platelet count can increase bruising or bleeding. Significant anemia can cause fatigue, weakness and shortness of breath.

Serious bone marrow toxicity can occur even with low dose methotrexate, particularly when drug exposure increases because of kidney impairment, interacting medications or dosing errors.

New unexplained bruising, bleeding, fever, persistent sore throat, severe fatigue or mouth ulcers should not simply be ignored while taking methotrexate.

Can Methotrexate Affect the Liver?

Yes.

Methotrexate can cause liver enzyme abnormalities and clinically important hepatotoxicity. Severe liver injury, fibrosis and cirrhosis have been reported with long term exposure.

At the same time, modern research has made the chronic liver risk more nuanced than older teaching sometimes suggested. Obesity, diabetes, metabolic dysfunction associated steatotic liver disease, substantial alcohol consumption, preexisting liver disease and other hepatotoxic medications can contribute importantly to the risk of liver abnormalities and fibrosis.

Some liver disease historically attributed entirely to methotrexate may therefore have reflected a combination of medication exposure and underlying metabolic or hepatic risk.

This does not make liver monitoring less important. It means physicians should evaluate the entire liver risk profile rather than treating cumulative methotrexate exposure as the only factor that matters.

Does Everyone Taking Methotrexate Need a Liver Biopsy?

No.

Routine liver biopsy was historically used much more frequently in patients receiving long term methotrexate, particularly for psoriasis.

Modern practice has moved increasingly toward risk based assessment, repeated laboratory testing and noninvasive methods of evaluating liver fibrosis when appropriate.

A patient with persistent liver test abnormalities or substantial metabolic or hepatic risk may require further evaluation.

Methotrexate should not be presented as a medication that automatically requires repeated liver biopsies simply because it is being used long term.

Can Someone Drink Alcohol While Taking Methotrexate?

Alcohol deserves caution because both alcohol and methotrexate can affect the liver.

Heavy alcohol use clearly increases concern for methotrexate hepatotoxicity. At lower levels of alcohol consumption, the available evidence is more nuanced, and recommendations vary according to dose, treatment duration, underlying liver health and other risk factors.

A patient should therefore discuss alcohol intake honestly with the prescribing physician rather than assuming that occasional alcohol is either completely harmless or universally prohibited.

Patients with significant alcohol use or alcohol related liver disease may not be appropriate candidates for methotrexate.

Why Does Kidney Function Matter?

Methotrexate is eliminated substantially through the kidneys.

When kidney function declines, methotrexate can remain in the body longer and drug exposure can increase, sometimes dramatically. Current prescribing information states that patients with renal impairment are at greater risk of adverse reactions and may require dose reduction, closer monitoring or discontinuation.

Dehydration, acute illness and medications that affect kidney function can also become important during treatment.

Kidney function should therefore not be treated as a one time baseline issue.

What About Pleural Effusions or Ascites?

Methotrexate can accumulate in significant collections of fluid outside the normal circulation, sometimes called third spaces.

Examples include pleural effusions around the lungs and ascites within the abdomen. Methotrexate can remain in these fluid compartments and return slowly to the bloodstream, prolonging drug elimination and increasing exposure.

Patients with significant pleural effusions or ascites therefore require special consideration before methotrexate treatment.

This is not a common issue for the typical otherwise healthy alopecia areata patient, but it is an important pharmacologic risk when these conditions are present.

Can Methotrexate Damage the Lungs?

Rarely, but importantly, yes.

Methotrexate can cause pulmonary toxicity, including acute or chronic interstitial pneumonitis. Severe and even fatal cases have been reported.

Methotrexate lung toxicity does not necessarily require years of treatment and can sometimes occur unpredictably.

New persistent dry cough, unexplained shortness of breath, fever or other respiratory symptoms developing during treatment deserve prompt medical evaluation.

These symptoms should not simply be assumed to represent a routine respiratory infection.

Does Methotrexate Increase the Risk of Infection?

Yes.

Methotrexate suppresses immune function and can increase susceptibility to bacterial, viral, fungal and opportunistic infections.

Serious infections reported with methotrexate include Pneumocystis pneumonia, invasive fungal infections, hepatitis B reactivation, tuberculosis and disseminated herpes zoster.

The absolute risk with low dose treatment in an otherwise healthy dermatology patient is different from the risk associated with high dose cancer treatment or multiple simultaneous immunosuppressive medications.

Still, significant active infection deserves attention, and recurrent or serious infection may require treatment interruption.

What About Vaccines?

Live vaccines are generally not recommended during methotrexate treatment because disseminated infection has occurred after live vaccination in immunosuppressed patients.

Vaccination status should ideally be reviewed before systemic therapy begins.

Nonlive vaccines can generally be administered, although methotrexate may reduce the immune response to some vaccines.

Patients should discuss vaccination timing with the treating physician rather than stopping methotrexate or delaying vaccination on their own.

What Are the Most Common Side Effects?

Common problems associated with low dose methotrexate can include:

• Nausea
• Abdominal discomfort
• Fatigue
• Mouth sores or stomatitis
• Reduced appetite
• Headache
• Dizziness
• Elevated liver enzymes

Some patients experience symptoms primarily on the day of treatment or the day after the weekly dose.

Folic acid supplementation and dose modification can sometimes improve tolerability. In broader low dose methotrexate practice, physicians may also alter dose timing, split a dose or use subcutaneous methotrexate when oral treatment is poorly tolerated. Those strategies come primarily from experience in other inflammatory diseases rather than alopecia areata specific trials.

Persistent or significant adverse effects deserve medical review rather than simply being accepted because methotrexate is controlling hair loss.

Can Methotrexate Cause Hair Loss?

It can.

Alopecia is a recognized adverse effect of methotrexate, although it occurs in only a minority of patients receiving low weekly doses.

This creates an unusual situation in hair loss treatment: a medication capable of suppressing the autoimmune process responsible for alopecia areata can itself occasionally contribute to diffuse hair thinning.

New diffuse shedding during methotrexate treatment should therefore not automatically be assumed to represent worsening alopecia areata. The pattern of loss, timing, disease activity and other possible causes should be evaluated.

Can Methotrexate Cause Mouth Sores?

Yes.

Stomatitis and oral ulceration are recognized methotrexate adverse effects and can sometimes signal excessive drug exposure or folate related toxicity.

Persistent or severe mouth ulcers deserve attention, particularly if they occur together with fever, bruising, bleeding or unusual fatigue.

Patients should not simply continue taking repeated weekly doses while significant mucosal toxicity is worsening without contacting the prescribing physician.

Can Methotrexate Cause Serious Skin Reactions?

Rarely, yes.

Severe dermatologic reactions including Stevens Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, skin necrosis and erythema multiforme have been reported with methotrexate. Some cases have been fatal.

These reactions are uncommon, especially in patients using low weekly doses, but new blistering, peeling skin, widespread painful rash, significant mucosal involvement or other rapidly progressive skin reactions require urgent medical evaluation.

Methotrexate can also produce photosensitivity or reactivate a previous severe sunburn response in some patients.

What Drug Interactions Are Especially Important?

Methotrexate has many clinically important interactions.

Medications that reduce renal clearance, alter protein binding or otherwise increase methotrexate exposure can increase toxicity. These can include certain antibiotics, proton pump inhibitors, probenecid, aspirin and some nonsteroidal anti inflammatory drugs.

Drugs with their own liver, kidney or bone marrow toxicity can compound methotrexate risk.

Patients should tell physicians, dentists and pharmacists that they are taking methotrexate before beginning a new prescription, antibiotic or procedure. Over the counter medications should also not automatically be assumed safe.

Why Are Trimethoprim and Co-trimoxazole Particularly Important?

Trimethoprim and the combination trimethoprim sulfamethoxazole deserve special attention.

These medications have antifolate effects that can combine with methotrexate’s effects on folate metabolism and bone marrow function. Co-trimoxazole can also alter methotrexate protein binding and renal handling.

Severe bone marrow suppression and pancytopenia, including fatal cases, have been reported when these medications were combined.

The combination should generally be avoided unless there is a compelling clinical reason and appropriate specialist supervision.

Patients should tell any physician prescribing an antibiotic that they are taking methotrexate.

What About Nitrous Oxide?

Nitrous oxide used during anesthesia or some dental procedures is another important interaction.

Nitrous oxide can potentiate methotrexate’s effects on folate dependent metabolic pathways and increase the risk of serious toxicity.

Current prescribing information advises avoiding nitrous oxide anesthesia in patients receiving methotrexate.

This is one reason patients should tell dentists, surgeons and anesthesiologists about methotrexate even when the procedure seems unrelated to their hair loss treatment.

Can NSAIDs Be Taken With Methotrexate?

This requires context.

Aspirin and nonsteroidal anti inflammatory drugs such as ibuprofen can reduce methotrexate elimination and increase exposure, particularly at higher methotrexate doses or when kidney function is impaired.

At the low weekly doses used in rheumatology and dermatology, physicians sometimes intentionally prescribe NSAIDs alongside methotrexate.

That does not mean a patient should freely add high doses of over the counter NSAIDs without discussing them with the treating physician.

Methotrexate dose, kidney function, other medications and the overall risk profile matter.

What About Cancer or Lymphoproliferative Disorders?

Current methotrexate prescribing information recognizes that secondary malignancies can occur during treatment.

Of particular interest with low dose methotrexate are uncommon lymphoproliferative disorders, which involve abnormal proliferation of lymphoid cells. These have been described most extensively in patients receiving methotrexate for autoimmune disease.

This should not be interpreted to mean that lymphoma is a common consequence of low dose methotrexate.

An unusual feature of some methotrexate associated lymphoproliferative disorders is that they have partially or completely regressed after methotrexate was discontinued, without immediate cancer directed treatment.

Persistent unexplained lymph node enlargement, fever, night sweats, unexplained weight loss or other concerning systemic symptoms deserve medical evaluation.

What About Pregnancy?

Methotrexate is contraindicated during pregnancy when used for noncancer conditions.

This is not merely a theoretical concern. Methotrexate can cause miscarriage, fetal death and serious developmental abnormalities.

Pregnancy status should be established before methotrexate treatment begins in women who could become pregnant.

For an elective condition such as alopecia areata, methotrexate should not be continued during pregnancy.

How Long Should Women Avoid Pregnancy After Methotrexate?

Current U.S. prescribing information advises women of reproductive potential to use effective contraception while taking methotrexate and for six months after the final dose.

Other international guidance for low dose methotrexate has sometimes used shorter preconception intervals, but the current U.S. prescribing information remains the appropriate conservative standard for a U.S. consumer resource.

A woman planning pregnancy should discuss discontinuation well before attempting conception rather than simply stopping methotrexate after becoming pregnant.

What About Men Taking Methotrexate Who Want Children?

This area requires an important distinction between U.S. product labeling and contemporary human pregnancy evidence.

Current U.S. prescribing information advises men with female partners of reproductive potential to use effective contraception during methotrexate treatment and for three months after the final dose. The label also states that methotrexate can cause chromosomal damage to sperm.

At the same time, modern observational data involving more than 2,000 paternal methotrexate exposures have been reassuring. Current British rheumatology guidance considers paternal exposure to low dose methotrexate up to 25 mg per week compatible with pregnancy and has not identified an increase in adverse fetal outcomes.

These positions are not identical.

For a U.S. patient, the conservative FDA labeling remains important and should be discussed with the prescribing physician. The human paternal exposure data are also relevant and should prevent the precautionary labeling from being misinterpreted as proof that paternal low dose methotrexate has been shown to cause birth defects.

Men planning conception should discuss the timing and necessity of treatment with their physician.

Can Methotrexate Affect Fertility?

It can affect reproductive function in some patients.

Current prescribing information acknowledges reports of menstrual dysfunction and impaired fertility in women, as well as oligospermia and infertility in men.

The extent, duration and reversibility are not completely predictable in every patient. This does not mean that permanent infertility is a common outcome of low dose methotrexate treatment.

The issue is nevertheless important because alopecia areata frequently affects adolescents and younger adults who may not otherwise think about fertility when beginning treatment for hair loss.

Reproductive planning should be discussed before treatment when relevant.

Can Methotrexate Be Used While Breastfeeding?

Current U.S. prescribing information recommends against breastfeeding during methotrexate treatment and for one week after the final dose.

Small amounts of methotrexate can enter human milk.

Because alopecia areata treatment is elective and methotrexate can cause serious toxicity, breastfeeding should not simply be continued on the assumption that a low weekly dose produces no infant exposure.

Can Methotrexate Be Used in Children or Adolescents?

Sometimes, but the evidence is substantially weaker than in adults.

Current international guidance advises against systemic methotrexate for mild or moderate alopecia areata in children and adolescents but allows it to be considered for severe or very severe disease.

When methotrexate is selected for severe pediatric alopecia areata, international guidance has described target dosing around 0.4 mg per kilogram per week.

Older pediatric studies and meta analyses have reported some meaningful responses, but the number of children studied is small and results have varied substantially. The older pooled evidence found a considerably lower complete response rate in children than in adults.

Adolescents age 12 and older with severe alopecia areata also now have an FDA approved systemic option in ritlecitinib, which changes the modern risk benefit discussion.

Is Methotrexate Used for Alopecia Totalis or Alopecia Universalis?

Yes.

Much of the methotrexate literature actually involves patients with severe disease, including alopecia totalis and alopecia universalis.

The 2023 randomized trial specifically involved patients with chronic AT or AU. Methotrexate alone produced limited complete regrowth in that difficult population, while combination treatment with low dose prednisone produced complete or nearly complete regrowth in a meaningful minority.

That does not establish methotrexate plus prednisone as the best treatment for AT or AU.

It demonstrates that even longstanding severe disease can sometimes respond to traditional systemic immunomodulatory therapy while also showing the limitations of methotrexate monotherapy in chronic refractory disease.

How Have JAK Inhibitors Changed the Role of Methotrexate?

The arrival of FDA approved JAK inhibitors has substantially changed treatment of severe alopecia areata.

Baricitinib and deuruxolitinib are FDA approved for adults with severe alopecia areata. Ritlecitinib is approved for adults and adolescents age 12 and older.

These medications were studied specifically for alopecia areata in large modern development programs and provide a more targeted long term systemic treatment approach than traditional nonspecific immunosuppressive therapy.

That does not make methotrexate obsolete.

Methotrexate has decades of experience, is inexpensive, can be useful as a steroid sparing medication and remains included in current international guidelines. It may also be considered when JAK inhibitors are contraindicated, unavailable, unaffordable or otherwise inappropriate.

The treatments should not be reduced to a simple hierarchy in which newer automatically means better or older automatically means safer. Their evidence, risk profiles, monitoring requirements, cost and suitability are different.

Can Methotrexate Be Combined With a JAK Inhibitor?

There is no established routine role for combining methotrexate with a JAK inhibitor for alopecia areata.

The major JAK inhibitor clinical development programs did not establish methotrexate plus JAK inhibition as a superior treatment strategy for hair regrowth. Product guidance for some JAK inhibitors also discourages combination with potent systemic immunosuppressive therapies.

Combining systemic immune modifying medications can increase infection and other safety risks.

A patient whose alopecia areata is inadequately controlled should not simply accumulate systemic medications. Treatment should generally be changed or combined only when there is a clear rationale and an evidence based understanding of the additional risk.

Is Methotrexate Used for Male or Female Pattern Hair Loss?

No.

Methotrexate is not a treatment for ordinary androgenetic alopecia.

Male and female pattern hair loss involve progressive follicular miniaturization and are not treated by nonspecific systemic immune suppression.

Using methotrexate simply because someone has extensive hair loss without establishing the diagnosis would expose that patient to unnecessary systemic risk.

Is Methotrexate Used for Telogen Effluvium?

No.

Ordinary telogen effluvium is not an autoimmune condition requiring methotrexate.

Diffuse shedding should be evaluated for causes such as illness, nutritional deficiency, thyroid disease, medication changes, hormonal changes and other physiological stressors.

Diffuse alopecia areata can sometimes resemble telogen effluvium, which is another reason diagnosis should come before systemic immune treatment.

What Should Be Evaluated Before Starting Methotrexate?

The first step is confirming that the patient actually has alopecia areata and that the disease is extensive or persistent enough to justify systemic treatment.

Disease extent should be documented with standardized photography and, where appropriate, SALT scoring.

Baseline medical evaluation should address complete blood count, liver function, kidney function, pregnancy potential, infection history, alcohol use, metabolic liver risk and current medications.

Patients with significant liver disease, substantial renal impairment, bone marrow disorders, serious active infection or other major risk factors may not be appropriate candidates.

Significant pleural effusions or ascites should also be identified because methotrexate can accumulate in these fluid compartments and be eliminated more slowly.

Vaccination status should be reviewed, and hepatitis, tuberculosis or other infection assessment may be appropriate according to the patient’s individual risk.

The objective is not simply to identify a medication capable of producing regrowth. It is to determine whether methotrexate is an appropriate systemic treatment for that particular patient.

Who Should Be Especially Cautious With Methotrexate?

Additional caution is appropriate in patients with:

• Significant liver disease
• Heavy alcohol use
• Obesity, diabetes or other metabolic liver risk
• Kidney impairment
• Abnormal blood counts or bone marrow disease
• Active serious infection
• Significant lung disease
• Pleural effusion or ascites
• Gastrointestinal ulceration
• Immunodeficiency
• Pregnancy or plans for pregnancy
• Breastfeeding
• Medications that interact with methotrexate
• Repeated or unexplained elevations in liver enzymes
• Other treatments capable of suppressing the immune system or bone marrow

Some of these conditions may represent strong reasons to avoid treatment entirely, while others require individualized assessment and closer monitoring.

What Symptoms Should Prompt Medical Attention?

Patients taking methotrexate should contact their physician for significant or unexplained symptoms such as:

• Fever or persistent signs of infection
• Severe or persistent mouth sores
• Unusual bruising or bleeding
• Marked fatigue or weakness
• Persistent nausea or vomiting
• Yellowing of the skin or eyes
• Dark urine
• New persistent cough
• Shortness of breath
• Widespread or severe rash
• Blistering or peeling skin
• Significant reduction in urination
• Persistent unexplained swollen lymph nodes
• Unexplained fever, night sweats or weight loss

These symptoms do not automatically mean serious methotrexate toxicity is occurring, but they should not be ignored.

What Should Someone Ask Before Starting Methotrexate?

Useful questions include:

• What is my actual diagnosis and disease severity?
• Why is methotrexate being recommended instead of local treatment or an FDA approved JAK inhibitor?
• Are we using methotrexate alone or with a corticosteroid?
• What weekly dose are we starting with?
• Which day of the week should I take it?
• Am I also supposed to take folic acid?
• What baseline blood tests do I need?
• How frequently will my blood count, liver tests and kidney function be checked?
• How long should I remain on treatment before we decide whether it is working?
• How will we measure the response?
• What happens if my hair regrows and methotrexate is reduced or stopped?
• Can I drink alcohol while taking it?
• Which antibiotics and over the counter medications should I avoid?
• What should I do if I develop mouth ulcers, fever, bruising, a new cough or a severe rash?
• Do my other medical conditions increase the risk of liver, kidney or bone marrow toxicity?
• What is the pregnancy or fertility plan if I want children?
• What is the long term strategy if methotrexate works?

The answers should be individualized rather than based on a generic autoimmune treatment protocol.

The AHLA Perspective

Methotrexate occupies an unusual but legitimate place in the treatment of alopecia areata.

It is not FDA approved for the disease, and its evidence base is less robust than the modern clinical development programs supporting approved JAK inhibitors. Much of its historical reputation in alopecia areata comes from retrospective studies and relatively small patient populations.

The modern randomized evidence provides an important reality check. In patients with chronic alopecia totalis and universalis, methotrexate alone produced very little complete regrowth. Adding low dose prednisone improved outcomes substantially in a minority of patients.

That does not mean methotrexate does not work. It means older pooled response percentages should not be interpreted as though they came from large controlled monotherapy trials.

Methotrexate remains a legitimate systemic treatment because it has decades of experience in autoimmune disease, remains included in current international alopecia areata guidelines and can function as a steroid sparing medication when longer term immune control is needed.

The most important distinction is between disease control and medication dependence.

Prednisone can suppress active alopecia areata quickly but generally cannot be maintained indefinitely without accumulating substantial systemic risk. Methotrexate may provide a slower systemic treatment strategy that allows corticosteroid exposure to be reduced in selected patients.

That does not make methotrexate risk free.

It can suppress the bone marrow. It can injure the liver. Kidney impairment and significant third space fluid accumulation can substantially increase drug exposure. Rare pulmonary toxicity and severe skin reactions can be serious. Pregnancy exposure can cause fetal harm. Important drug interactions can dramatically increase toxicity. Reproductive considerations apply to both women and men.

And perhaps most importantly from a basic medication safety standpoint, methotrexate used for autoimmune disease is generally taken once weekly. Taking a weekly dose every day has caused fatal poisoning.

The arrival of JAK inhibitors has changed how physicians should think about long term systemic therapy for severe alopecia areata, but it has not erased every role for traditional immunomodulators.

Methotrexate may still make sense when a patient has moderate to severe disease, when systemic corticosteroid dependence needs to be avoided, when newer medications are inappropriate or inaccessible, or when a physician believes that its long clinical experience and individual risk profile make it a reasonable choice.

The objective should not be to use methotrexate simply because it is inexpensive or because it has been prescribed for alopecia areata for many years.

The objective is to establish the diagnosis, define disease severity, choose a systemic treatment whose expected benefit justifies its risks, monitor that treatment carefully and use the lowest effective sustainable strategy that controls the disease without exposing the patient to unnecessary long term toxicity.

Used for: Alopecia Areata

Selected References

1. Blume-Peytavi U, Constantinou A, Tomova-Simitchieva T, et al. S3 Guideline Diagnostics and Therapy in Alopecia Areata, Part 2: Therapy, Psychosocial and Cosmetic Support. J Dtsch Dermatol Ges. 2026;24:e1155-e1177. doi:10.1111/ddg.70130x. PubMed
2. Harries MJ, Ahmed A, Ascott A, et al. British Association of Dermatologists Living Guideline for Managing People With Alopecia Areata 2025. British Journal of Dermatology. 2026;194:e56-e73. doi:10.1093/bjd/ljaf452. British Journal of Dermatology
3. Joly P, Lafon A, Houivet E, et al. Efficacy of Methotrexate Alone vs Methotrexate Plus Low-Dose Prednisone in Patients With Alopecia Areata Totalis or Universalis: A 2-Step Double-Blind Randomized Clinical Trial. JAMA Dermatology. 2023;159:403-410. doi:10.1001/jamadermatol.2022.6687. PubMed
4. Phan K, Ramachandran V, Sebaratnam DF. Methotrexate for Alopecia Areata: A Systematic Review and Meta-Analysis. Journal of the American Academy of Dermatology. 2019;80:120-127.e2. doi:10.1016/j.jaad.2018.06.064. PubMed
5. U.S. National Library of Medicine. Methotrexate Tablets: Full Prescribing Information. Includes once weekly dosing precautions, embryo fetal toxicity, myelosuppression, hepatotoxicity, pulmonary toxicity, renal toxicity, severe dermatologic reactions, serious infections, malignancy, vaccination, drug interactions, third space accumulation, fertility and lactation guidance. DailyMed Prescribing Information
6. British Society for Rheumatology. 2025 British Society for Rheumatology Guideline for the Prescription and Monitoring of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs. Rheumatology. 2026;65:keaf522. Rheumatology
7. Russell MD, Dey M, Flint J, et al. British Society for Rheumatology Guideline on Prescribing Drugs in Pregnancy and Breastfeeding: Immunomodulatory Anti-Rheumatic Drugs and Corticosteroids. Rheumatology. 2023;62:e48-e88. Rheumatology
8. Rudnicka L, Arenbergerova M, Grimalt R, et al. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata. Journal of the European Academy of Dermatology and Venereology. 2024;38:687-694. doi:10.1111/jdv.19768. PubMed
9. U.S. National Library of Medicine. Methotrexate. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. LiverTox